鶹ý

ADA Advises Against Compounded GLP-1s; Growth Hormone Therapy Guide; T1D Outcomes Up

— News and commentary from the endocrinology world

MedpageToday
Endo Break over a computer rendering of a man with illustrated body organs.

The American Diabetes Association (ADA) urged healthcare providers against prescribing non-FDA approved for type 2 diabetes or obesity and instead recommended switching to a different FDA-approved medication if an agent is unavailable. (Diabetes Care)

Patients with hypothyroidism averaged a 0.36 mU/L to 0.55 mU/L reduction in their thyroid-stimulating hormone levels, according to data in Epic Research.

A consensus group of international pediatric endocrinology experts released guidance on in children with growth hormone deficiency. (Journal of Clinical Endocrinology & Metabolism)

In an emulated target trial of nearly 1 million Swedish women ages 50-58, was tied with an increased risk of ischemic heart disease and venous thromboembolism. (The BMJ)

Testosterone levels above minimum threshold concentrations for men , a small study found. (Proceedings of the Royal Society B)

Here's how air pollution may be . (Washington Post)

Canada for risk reduction of non-fatal heart attacks in adults with established cardiovascular disease and a BMI of 27 or above, said maker Novo Nordisk.

Transgender people under the next Trump administration are stockpiling their medication. (The Guardian)

In an international longitudinal analysis of children with type 1 diabetes (T1D), and use of diabetes technology increased from 2013 to 2022. (The Lancet Diabetes & Endocrinology)

  • author['full_name']

    Kristen Monaco is a senior staff writer, focusing on endocrinology, psychiatry, and nephrology news. Based out of the New York City office, she’s worked at the company since 2015.